Efficacy of concurrent chemoradiotherapy combined with nimotuzumab in the treatment of nasopharyngeal carcinoma with cervical lymph node metastasis
Authors:
- 29 December 2022
- journal article
- research article
- Published by Springer Nature in European Archives of Oto-Rhino-Laryngology
- Vol. 280 (5) , 2479-2488
Abstract
Objectives First, we retrospectively compared the clinical efficacy of concurrent chemoradiotherapy combined with nimotuzumab vs. chemoradiotherapy alone in patients with nasopharyngeal carcinoma (NPC) and cervical lymph node metastasis. Second, we analyzed the value of Ki-67 as a predictor of nimotuzumab efficacy. Methods From January 2012 to December 2019, 1250 patients with cervical lymph node metastasis eligible for enrollment were included, of whom 383 were treated with concurrent chemoradiotherapy combined with nimotuzumab (targeted therapy group), and 867 were treated with concurrent chemoradiotherapy (CRT group). A total of 381 pairs of patients were matched using 1:1 propensity score matching, and differences in clinical prognosis were compared between the two groups. Results Overall survival (OS) (P = 0.028), disease-free survival (DFS) (P = 0.040), and distant metastasis-free survival (DMFS) (P = 0.040) were better in the targeted therapy compared to the CRT group. Multivariate analysis revealed that clinical staging, chemotherapy, and nimotuzumab therapy were predictors of OS and DFS. In the targeted therapy group, patients with ≥ 50% Ki-67 positivity had better OS and DFS rates than those with < 50% Ki-67 positivity. Conclusions In patients with stage N1–3 NPC and lymph node metastasis, the addition of nimotuzumab to concurrent chemoradiotherapy may provide additional survival benefits. Ki-67 is a potential biomarker with clinical predictive value for the efficacy of nimotuzumab combined with chemoradiotherapy.Keywords
This publication has 30 references indexed in Scilit:
- Effects of ADAM10 upregulation on progression, migration, and prognosis of nasopharyngeal carcinomaCancer Science, 2015
- Prognostic value of TROP2 in human nasopharyngeal carcinoma.2015
- An Intronic microRNA Links Rb/E2F and EGFR SignalingPLOS Genetics, 2014
- Assessment of early changes in 3H-fluorothymidine uptake after treatment with gefitinib in human tumor xenograft in comparison with Ki-67 and phospho-EGFR expressionBMC Cancer, 2013
- Prognostic scoring system for locoregional control among the patients with nasopharyngeal carcinoma treated by intensity-modulated radiotherapyChinese Journal of Cancer, 2013
- The expression of epidermal growth factor receptor and Ki67 in primary and relapse nasopharyngeal cancer: a micro-evidence for anti-EGFR targeted maintenance therapyMedical Oncology, 2011
- HPV-associated head and neck cancer: a virus-related cancer epidemicThe Lancet Oncology, 2010
- The contribution of cetuximab in the treatment of recurrent and/or metastatic head and neck cancerBiologics: Targets and Therapy, 2010
- Randomized Trial of Radiotherapy Versus Concurrent Chemoradiotherapy Followed by Adjuvant Chemotherapy in Patients With American Joint Committee on Cancer/International Union Against Cancer Stage III and IV Nasopharyngeal Cancer of the Endemic VarietyJournal of Clinical Oncology, 2005
- Epidermal growth factor receptor and its inhibition in radiotherapy:in vivofindingsInternational Journal of Radiation Biology, 2003